Advertisement
DERM vs ETON
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DERM is a Hold and ETON is a Hold.
DERM in downward trend: price dove below 50-day moving average on September 23, 2026
DERM moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 51 of 56 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DERM as a result. In 82 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The 10-day moving average for DERM crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DERM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for DERM entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where DERM's RSI Oscillator exited the oversold zone, 25 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 12 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where DERM advanced for three days, in 231 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
DERM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.474) is normal, around the industry mean (10.407). P/E Ratio (-23.136) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (2.865) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. DERM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DERM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
ETON in downward trend: price dove below 50-day moving average on October 06, 2026
ETON moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend. In 25 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ETON as a result. In 75 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The 10-day moving average for ETON crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 10 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for ETON entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ETON's RSI Indicator exited the oversold zone, 19 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +0.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ETON advanced for three days, in 245 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
ETON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ETON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (30.691) is normal, around the industry mean (10.407). P/E Ratio (108.739) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (15.798) is also within normal values, averaging (178.797).
DERM | ETON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 59 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 14 Undervalued | 89 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 9 | |
SMR RATING 1..100 | 96 | 28 | |
PRICE GROWTH RATING 1..100 | 82 | 35 | |
P/E GROWTH RATING 1..100 | 17 | 19 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DERM's Valuation (14) in the Biotechnology industry is significantly better than the same rating for ETON (89) in the Pharmaceuticals Major industry. This means that DERM’s stock grew significantly faster than ETON’s over the last 12 months.
ETON's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is significantly better than the same rating for DERM (100) in the Biotechnology industry. This means that ETON’s stock grew significantly faster than DERM’s over the last 12 months.
ETON's SMR Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for DERM (96) in the Biotechnology industry. This means that ETON’s stock grew significantly faster than DERM’s over the last 12 months.
ETON's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for DERM (82) in the Biotechnology industry. This means that ETON’s stock grew somewhat faster than DERM’s over the last 12 months.
DERM's P/E Growth Rating (17) in the Biotechnology industry is in the same range as ETON (19) in the Pharmaceuticals Major industry. This means that DERM’s stock grew similarly to ETON’s over the last 12 months.
| DERM | ETON | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 86% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 77% |
| MACD ODDS (%) | N/A | N/A |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 80% |
| Advances ODDS (%) | 4 days ago 85% | 12 days ago 84% |
| Declines ODDS (%) | 8 days ago 84% | 5 days ago 79% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DERM’s FA Score shows that 2 FA rating(s) are green while ETON’s FA Score has 3 green FA rating(s).
- DERM’s FA Score: 2 green, 3 red.
- ETON’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DERM’s TA Score shows that 4 TA indicator(s) are bullish while ETON’s TA Score has 4 bullish TA indicator(s).
- DERM’s TA Score: 4 bullish, 5 bearish.
- ETON’s TA Score: 4 bullish, 5 bearish.
Price Growth
DERM (@Pharmaceuticals: Generic) experienced а -0.68% price change this week, while ETON (@Pharmaceuticals: Generic) price change was -2.55% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.53%. For the same industry, the average monthly price growth was -10.53%, and the average quarterly price growth was +7.85%.
Reported Earning Dates
DERM is expected to report earnings on Nov 11, 2026.
ETON is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.53% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
DERM and
Correlation & Price change
A.I.dvisor indicates that over the last year, DERM has been loosely correlated with APUS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if DERM jumps, then APUS could also see price increases.
| Ticker / NAME | Correlation To DERM | 1D Price Change % | ||
|---|---|---|---|---|
| DERM | 100% | +6.04% | ||
| APUS - DERM | 49% Loosely correlated | -2.77% | ||
| CHRS - DERM | 27% Poorly correlated | +2.94% | ||
| CRDL - DERM | 23% Poorly correlated | -1.71% | ||
| AMLX - DERM | 23% Poorly correlated | -1.58% | ||
| ETON - DERM | 23% Poorly correlated | +1.46% | ||
More | ||||
ETON and
Correlation & Price change
A.I.dvisor indicates that over the last year, ETON has been loosely correlated with MDGL. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ETON jumps, then MDGL could also see price increases.
| Ticker / NAME | Correlation To ETON | 1D Price Change % | ||
|---|---|---|---|---|
| ETON | 100% | +1.46% | ||
| MDGL - ETON | 34% Loosely correlated | -1.01% | ||
| VKTX - ETON | 31% Poorly correlated | -2.08% | ||
| SIGA - ETON | 30% Poorly correlated | +0.96% | ||
| ARRY - ETON | 30% Poorly correlated | -3.23% | ||
| FDMT - ETON | 29% Poorly correlated | -6.10% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TEQI | 52.85 | 0.31 | +0.58% |
| T. Rowe Price Equity Income ETF (TEQI) | |||
| USTB | 50.06 | 0.15 | +0.30% |
| VictoryShares Short-Term Bond ETF (USTB) | |||
| CGO | 12.60 | N/A | N/A |
| Calamos Global Total Return Fund | |||
| SKRE | 6.57 | -0.35 | -5.07% |
| Tuttle Capital Daily 2X Inverse Regional Banks ETF (SKRE) | |||
| MARO | 2.45 | -0.17 | -6.49% |
| Yieldmax Mara Option Income Strategy ETF | |||